Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Cassava Sciences Inc

Company price
None USD 0.00(0%)
Last update at 2026-06-11T22:02:13.887094Z
Market Cap
1039.64M

Momentum Score

…

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
12.32
Low
32.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.21
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-68.03M
Debt / Equity
0.00
ROE
-33.90%
Net Debt
-121.14M
ROCE
-59.16%
Diluted EPS TTM
-2.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -76.25M -32.38M -6.33M -4.63M -6.56M
Net income -72.47M -31.80M -5.85M -4.25M -6.56M
Selling general administrative 11.99M 8.05M 3.74M 3.39M 3.69M
Gross profit -0.00M - -0.35M -1.57M -2.97M
Reconciled depreciation 1.30M 0.53M 0.02M 0.06M 0.07M
Ebit -81.32M -33.40M -6.45M -5.02M -6.73M
Ebitda -80.02M -32.87M -7.14M -4.96M -6.66M
Depreciation and amortization 1.30M 0.53M -0.69M 0.06M 0.07M
Non operating income net other - 0.48M 0.11M 0.33M 0.10M
Operating income -80.02M -32.87M -6.45M -4.96M -6.66M
Other operating expenses 80.02M 32.87M 6.79M 4.96M 6.66M
Interest expense -3.77M 0.48M 0.00M 0.00M 0.00M
Interest income 2.78M 0.05M 0.11M 0.33M 0.10M
Net interest income 2.78M 0.05M 0.11M 0.33M 0.10M
Non recurring - - -0.35M - -
Income tax expense -3.77M -0.58M -0.48M -0.39M -0.10M
Total revenue -0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 80.02M 32.87M 6.79M 4.96M 6.66M
Cost of revenue - - 0.35M 1.57M 2.97M
Total other income expense net 3.77M 0.48M 0.11M 0.33M 0.10M
Net income from continuing ops -76.25M -32.38M -6.33M -4.63M -6.56M
Net income applicable to common shares -76.25M -32.38M -6.33M -4.63M -6.56M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 151.66M 234.83M 266.78M 94.30M 23.49M
Intangible assets 0.18M 0.62M 1.07M - -
Other current assets 7.54M 10.21M 11.04M 0.49M 0.27M
Total liab 14.20M 7.29M 12.87M 2.10M 1.39M
Total stockholder equity 137.47M 227.54M 253.91M 92.20M 22.10M
Other current liab 3.62M 2.94M 0.63M 0.09M 0.01M
Common stock 0.04M 511.09M 461.22M 267.12M 190.69M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.02M
Retained earnings -380.77M -283.55M -207.31M -174.92M -168.59M
Other liab - 0.20M 0.19M - -
Other assets - - 0.40M 0.29M -
Cash 121.14M 201.01M 233.44M 93.51M 23.08M
Total current liabilities 14.20M 7.06M 12.53M 1.86M 1.39M
Current deferred revenue - - 4.68M 0.80M 0.83M
Net debt -121.14M -200.88M -233.20M -93.21M -22.99M
Short term debt - 0.10M 0.10M 0.06M 0.09M
Short long term debt total - 0.14M 0.24M 0.29M 0.09M
Other stockholder equity 518.20M 511.05M 461.18M 267.09M 191.56M
Property plant equipment - 22.99M 20.83M 0.31M 0.05M
Total current assets 129.63M 211.23M 244.48M 93.99M 23.35M
Net tangible assets - 226.92M 252.84M 92.20M 22.10M
Net receivables 0.96M - - - -
Accounts payable 10.57M 4.02M 7.13M 0.91M 0.45M
Accumulated other comprehensive income 0.00M - - - -0.90M
Common stock total equity - - 0.04M 0.04M 0.02M
Retained earnings total equity - - -207.31M -174.92M -168.59M
Non currrent assets other - - 0.40M 0.29M 0.09M
Non current assets total 22.03M 23.61M 22.30M 0.31M 0.14M
Capital lease obligations 0.00M 0.14M 0.24M 0.29M 0.09M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.71M -22.21M 0.36M -0.02M 0.00M
Change to liabilities -3.45M 10.82M 0.46M 0.79M -0.62M
Total cashflows from investing activities -2.71M -22.21M 0.36M -0.02M -0.02M
Total cash from financing activities 47.80M 192.34M 75.45M 5.81M 14.10M
Change to operating activities -1.19M -6.32M -0.17M 0.60M -0.54M
Net income -76.25M -32.38M -6.33M -4.63M -6.56M
Change in cash -32.42M 139.93M 70.42M 3.27M 9.33M
Begin period cash flow 233.44M 93.51M 23.08M 19.81M 10.48M
End period cash flow 201.01M 233.44M 93.51M 23.08M 19.81M
Total cash from operating activities -77.51M -30.20M -5.38M -2.51M -4.77M
Issuance of capital stock 47.33M 190.52M 70.25M 0.00M 14.10M
Depreciation 1.30M 0.53M 0.02M 0.06M 0.07M
Other cashflows from investing activities - - 0.36M - -
Sale purchase of stock - 192.34M 5.20M 5.81M 14.10M
Other cashflows from financing activities 0.47M 1.82M 5.20M 5.87M -0.06M
Change to netincome 2.07M 1.76M 0.64M 1.30M 2.39M
Capital expenditures 2.71M 22.21M 0.35M 0.02M 0.02M
Cash flows other operating - -10.93M -0.22M -0.02M -0.05M
Cash and cash equivalents changes - 139.93M 70.42M 3.27M 9.33M
Change in working capital -4.63M -0.10M 0.29M 0.76M -0.67M
Stock based compensation 2.07M 1.76M 0.99M 1.30M 2.39M
Other non cash items - -139.92M -0.35M -1.67M -10.67M
Free cash flow -80.23M -52.41M -5.38M -2.53M -4.77M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

6801 N. Capital of Texas Highway, Austin, TX, United States, 78731

512 501 2444

29

Name Title Year Born
Mr. Remi Barbier Founder, Chairman, Pres & CEO 1960
Mr. Eric J. Schoen Chief Financial Officer 1968
Dr. Nadav Friedmann M.D., Ph.D. Chief Medical Officer & Director 1943
Dr. James W. Kupiec M.D. Chief Clinical Devel. Officer NA
Dr. George Thornton Sr. VP of Technology NA
Mr. R. Christopher Cook Sr. VP & Gen. Counsel NA
Mr. Michael Zamloot Sr. VP of Technical Operations NA
Dr. Michael Marsman Pharm.D. Sr. VP of Regulatory Affairs NA
Dr. Lindsay H. Burns Ph.D. Sr. VP of Neuroscience NA
Mr. Remi Barbier Founder, Chairman, President & CEO 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…